Tectonic Therapeutic, Inc. (TECX)

Market Cap	543.70M
Revenue (ttm)	n/a
Net Income (ttm)	-45.82M
Shares Out	14.73M
EPS (ttm)	-3.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	106,801
Open	37.40
Previous Close	37.40
Day's Range	36.33 - 37.70
52-Week Range	1.40 - 37.99
Beta	n/a
Analysts	Strong Buy
Price Target	60.00 (+62.6%)
Earnings Date	Nov 24, 2024

About TECX

Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company’s pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangie...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 21, 2018
• Employees: 44
• Stock Exchange: NASDAQ
• Ticker Symbol: TECX
• Website: https://tectonictx.com

Financial Performance

Financial numbers in USD

Analyst Forecast

According to 4 analysts, the average rating for TECX stock is "Strong Buy." The 12-month stock price forecast is $60.0, which is an increase of 62.60% from the latest price.

Price Target

$60.0

(62.60% upside)

Analyst Consensus: Strong Buy